EMA Panel Backs BRAFTOVI for Metastatic Colorectal Cancer

Pierre Fabre Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX as a first-line treatment for adults with BRAFV600E-mutant metastatic colorectal cancer (mCRC), potentially paving the way for a new targeted treatment option in Europe.

The recommendation will now be reviewed by the European Commission, which is expected to make a final decision on marketing authorization in the European Union later this year. If approved, the regimen would become the first and only targeted therapy authorized in the EU for patients with BRAFV600E-mutant metastatic colorectal cancer in the first-line treatment setting.

The positive opinion marks a significant regulatory milestone for Pierre Fabre Laboratories and reflects growing momentum toward personalized treatment strategies in colorectal cancer, particularly for patients with aggressive molecular subtypes linked to poor outcomes.

BRAFV600E-mutant metastatic colorectal cancer is a difficult-to-treat form of colorectal cancer characterized by a mutation in the BRAF gene that drives tumor growth. Patients with this mutation generally face worse prognoses and limited treatment options compared with individuals without the mutation. Existing first-line treatment approaches typically involve chemotherapy combinations, with or without targeted biologics, but survival outcomes remain suboptimal.

The CHMP recommendation was based on findings from the Phase 3 BREAKWATER clinical trial, which evaluated the efficacy and safety of BRAFTOVI in combination with cetuximab and mFOLFOX6 in previously untreated patients with BRAFV600E-mutant mCRC. The study compared the regimen against standard oxaliplatin-based chemotherapy, administered either alone or with bevacizumab.

According to trial results, the combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the study’s primary endpoints. Patients receiving BRAFTOVI in combination with cetuximab and mFOLFOX6 achieved a median progression-free survival of 12.8 months, compared with 7.1 months in patients treated with chemotherapy, with or without bevacizumab.

The regimen reduced the risk of disease progression or death by 47%, reflected in a hazard ratio of 0.53. Investigators also reported statistically significant improvements in overall response rate (ORR), another dual primary endpoint, indicating a stronger tumor response in patients receiving the targeted regimen.

Pierre Fabre executives described the CHMP recommendation as an important step toward improving care for patients with this specific form of metastatic colorectal cancer.

Eric Ducournau, chief executive officer of Pierre Fabre Laboratories, said the positive opinion reinforces the company’s commitment to developing meaningful oncology innovations for patients with high unmet medical needs. He noted that if approved, the treatment would represent a unique targeted option for patients with BRAFV600E-mutant disease at the first-line stage, when treatment decisions may significantly affect long-term outcomes.

The recommendation also highlights the increasing role of biomarker-driven therapies in oncology, where treatment decisions are guided by specific genetic mutations present in tumors. Precision medicine approaches have expanded rapidly across cancer care, allowing clinicians to tailor therapies to patient subgroups most likely to benefit.

A final decision from the European Commission is expected later this year, and approval could provide clinicians across Europe with a new frontline treatment strategy for a patient population that currently faces limited targeted therapeutic options.